Oxytocin vs oral misoprostol for PROM induction in nulliparas with unfavorable cervix: a randomized trial

What Was Tested

The paper reports a study of Oxytocin, published as a randomized controlled trial.

To determine if oxytocin or oral misoprostol results in a shorter time to delivery among nulliparous patients with an unfavorable cervical examination and PROM diagnosis and to evaluate patient satisfaction with both methods.

Why It Was Studied

Induction of labor (IOL) is recommended following prelabor rupture of membranes (PROM).

The optimal method for IOL and need for cervical ripening in those with PROM and an unfavorable cervical examination is unclear.

Who Took Part

According to the abstract, 148 subjects were involved.

The age groups tagged for this paper are adults, women only.

Secondary outcomes included suspected intraamniotic infection, cesarean delivery, composite maternal and neonatal morbidity, and patient satisfaction (assessed by Birth Satisfaction Scale-Revised).

The study was stopped early by the data safety monitoring board due to feasibility concerns in recruiting desired sample size.

How the Study Was Run

The researchers set it up as a randomized study.

Because people in this Oxytocin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

This is a randomized clinical trial conducted at an urban tertiary care center from 2019 to 2023.

The primary outcome was time from IOL to delivery in hours compared between oxytocin vs oral misoprostol.

Sub-group analyses for those with BMI ≥ 30 kg/m2 and cervical dilation ≥1 cm were performed.

What Was Measured

PubMed files the paper under topics including Misoprostol, Labor, Induced, Oxytocin, Oxytocics, Patient Satisfaction, Premature Rupture of Fetal Membranes and Cervical Ripening.

The authors tagged it with the keywords prelabor rupture of membranes.

What This Means in Plain Language

The paper is a randomized study of Oxytocin in 148 subjects.

The abstract goes on to report its results in about 10 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2024 (American journal of obstetrics & gynecology MFM), a journal based in United States.

More context: the Oxytocin compound page, all human trials.